BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.98%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.46B
AUM Growth
+$4.46B
(-14%)
Cap. Flow
-$467M
Cap. Flow
% of AUM
-10.47%
Top 10 Holdings %
Top 10 Hldgs %
48.58%
Holding
170
New
10
Increased
26
Reduced
81
Closed
22
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$50.6M |
| 2 |
AbbVie
ABBV
|
$18.9M |
| 3 |
Stryker
SYK
|
$17.3M |
| 4 |
Beam Therapeutics
BEAM
|
$17.1M |
| 5 |
Baxter International
BAX
|
$15.6M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$204M |
| 2 |
Arvinas
ARVN
|
$45.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$36.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$32.2M |
| 5 |
Tandem Diabetes Care
TNDM
|
$28.2M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Technology | 0.01% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
GE HealthCare
GEHC
$33.7B
| $42.3M | 0.95% | 524,414 | – | – |
|
27
Cigna
CI
$80.3B
| $38.7M | 0.87% | 117,535 -7,670 | -6% | -$2.52M |
|
28
ResMed
RMD
$40.2B
| $37.1M | 0.83% | 165,802 +5,009 | +3% | +$1.12M |
|
29
Immunocore
IMCR
$1.62B
| $36.3M | 0.81% | 1,221,794 +16,330 | +1% | +$485K |
|
30
Eli Lilly
LLY
$657B
| $36M | 0.81% | 43,647 -1,818 | -4% | -$1.5M |
|
31
Wave Life Sciences
WVE
$1.53B
| $33.1M | 0.74% | 4,094,458 | – | – |
|
32
Zimmer Biomet
ZBH
$21B
| $33M | 0.74% | 291,346 -2,275 | -0.8% | -$257K |
|
33
Idexx Laboratories
IDXX
$51.8B
| $32.3M | 0.72% | 76,897 -38 | -0% | -$16K |
|
34
Thermo Fisher Scientific
TMO
$186B
| $32M | 0.72% | 64,232 +3,270 | +5% | +$1.63M |
|
35
Edgewise Therapeutics
EWTX
$1.51B
| $31.4M | 0.7% | 1,428,929 | – | – |
|
36
Cooper Companies
COO
$13.4B
| $30.1M | 0.67% | 357,025 -105 | -0% | -$8.86K |
|
|
37
AbbVie
ABBV
$372B
| $28.3M | 0.63% | 135,240 +89,981 | +199% | +$18.9M |
|
38
Veeva Systems
VEEV
$44B
| $26.2M | 0.59% | 113,250 -14,325 | -11% | -$3.32M |
|
39
BioMarin Pharmaceuticals
BMRN
$11.2B
| $26M | 0.58% | 368,373 +39,352 | +12% | +$2.78M |
|
40
Danaher
DHR
$147B
| $25.5M | 0.57% | 124,321 +4,399 | +4% | +$902K |
|
41
Amgen
AMGN
$155B
| $25.2M | 0.57% | 80,935 -8,305 | -9% | -$2.59M |
|
42
Exact Sciences
EXAS
$8.98B
| $25.1M | 0.56% | 579,074 -114,982 | -17% | -$4.98M |
|
43
Molina Healthcare
MOH
$9.8B
| $25M | 0.56% | 75,895 -6,256 | -8% | -$2.06M |
|
44
Steris
STE
$24.1B
| $24.9M | 0.56% | 109,887 | – | – |
|
45
Globus Medical
GMED
$8.27B
| $24.3M | 0.55% | 332,336 -30,643 | -8% | -$2.24M |
|
46
Procept Biorobotics
PRCT
$2.23B
| $24.2M | 0.54% | 414,923 -47,971 | -10% | -$2.79M |
|
47
Align Technology
ALGN
$10.3B
| $24M | 0.54% | 150,993 -9,010 | -6% | -$1.43M |
|
48
HCA Healthcare
HCA
$94.5B
| $21.4M | 0.48% | 61,807 -76 | -0.1% | -$26.3K |
|
49
Merck
MRK
$210B
| $20.8M | 0.47% | 231,371 -32,855 | -12% | -$2.95M |
|
50
McKesson
MCK
$85.4B
| $20.6M | 0.46% | 30,580 +11,265 | +58% | +$7.58M |
|